Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Pri

Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Primary Advanced/Recurrent Endometrial Cancer

The Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair-deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Related Keywords

, Glaxosmithkline , Regulatory Agency , Healthcare Products Regulatory Agency , Yellow Card , Dostarlimab In Combination With Chemotherapy , Patients With Mismatch Repair Deficient Microsatellite Instability High Primary Advanced Or Recurrent Endometrial Cancer , Ruby Trial , Nct03981796 ,

© 2025 Vimarsana